Rozrolimupab: Phase II data

A dose-escalation, open-label Phase II trial in 38 evaluable Rhesus D (RhD)-positive, non-splenectomized patients

Read the full 144 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE